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Abstract
Background and Objective Alemtuzumab  (Campath®) is used to prevent graft-versus-host disease and graft failure following 
pediatric allogeneic hematopoietic cell transplantation. The main toxicity includes delayed immune reconstitution, subsequent 
viral reactivations, and leukemia relapse. Exposure to alemtuzumab is highly variable upon empirical milligram/kilogram dosing.
Methods A population pharmacokinetic (PK) model for alemtuzumab was developed based on a total of 1146 concentra-
tion samples from 206 patients, aged 0.2–19 years, receiving a cumulative intravenous dose of 0.2–1.5 mg/kg, and treated 
between 2003 and 2015 in two centers.
Results Alemtuzumab PK were best described using a two-compartment model with a parallel saturable and linear elimina-
tion pathway. The linear clearance pathway, central volume of distribution, and intercompartmental distribution increased 
with body weight. Blood lymphocyte counts, a potential substrate for alemtuzumab, did not impact clearance.
Conclusion The current practice with uniform milligram/kilogram doses leads to highly variable exposures in children due to the non-
linear relationship between body weight and alemtuzumab PK. This model may be used for individualized dosing of alemtuzumab.
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Key Points 
Alemtuzumab pharmacokinetics (PK) can be predicted 
using a population PK model, being the first step towards 
an individualized dosing regimen.
Body weight is the most important covariate predicting 
PK.
Blood lymphocyte counts, being a potential substrate for 
alemtuzumab, do not impact clearance.
 R. Admiraal et al.
1 Introduction
Allogeneic hematopoietic cell transplantation (HCT) is a 
potentially curative treatment option for children with a 
variety of underlying diseases, including malignancies and 
benign disorders. Approaches to reduce mortality are essen-
tial, including the prevention of graft-versus-host disease 
(GvHD), which contributes to morbidity and mortality fol-
lowing HCT [1, 2].
Alemtuzumab  (Campath®), a humanized anti-CD52 mon-
oclonal antibody, was introduced as serotherapy to prevent 
GvHD and graft failure by in vivo depletion of lymphocytes 
[3]. The inclusion of alemtuzumab in the conditioning regi-
men significantly reduces the incidence of both acute and 
chronic GvHD [4–6]. An exposure-dependent relationship 
between alemtuzumab concentrations and acute GvHD was 
reported [1]. Conversely, higher doses of alemtuzumab have 
been associated with delayed immune reconstitution (IR) by 
excessive lymphodepletion [7, 8]. IR, especially of T cells, 
is dependent on peripheral expansion of graft-infused cells 
during the first months after HCT; depletion of these T cells 
may leave patients with no or little IR [9], which could 
potentially lead to increased viral reactivations as well as 
less graft-versus-leukemia effect, thereby abrogating the 
beneficial effect of GvHD reduction on overall survival 
(OS). Despite a reduced incidence of GvHD, the absence of 
improvement in OS with the inclusion of alemtuzumab may 
be due to delayed T-cell IR [1, 4, 5, 8, 10–12]. Moreover, 
most studies report on alemtuzumab pharmacology in adult 
populations; few studies have been performed in pediatric 
populations.
While evidence suggests a relationship between the use 
of alemtuzumab and clinical outcomes in adult populations, 
individual exposure of alemtuzumab is unpredictable due 
to highly variable pharmacokinetics (PK) [13–16] with 
the currently applied fixed empirical dosing in adults. As 
a consequence, patients treated with a comparable dose of 
alemtuzumab may have significant differences in drug expo-
sure and, consequently, clinical outcome. Mostly descriptive 
PK of alemtuzumab are available in pediatric populations 
[17, 18], while variability in PK is often most substantial 
in children [19, 20]. The variable PK and their potential 
associations with outcome underline the need for predictable 
exposure to antibodies in all patients [13, 21–24]. Accord-
ingly, the importance of dose individualization and/or thera-
peutic drug monitoring (TDM) of monoclonal antibodies is 
increasingly recognized [25, 26].
There is a great need for a population PK model for alem-
tuzumab in children in order to understand the PK. In future, 
dosing may be amended based on this PK model. In this 
study, we describe the population PK of alemtuzumab in 
children receiving an HCT as a first step to developing an 
individualized dosing regimen.
2  Methods
2.1  Study Design and Patients
Patients receiving an HCT with alemtuzumab as part of their 
conditioning, and treated at the pediatric wards of the Leiden 
University Medical Center (LUMC), Leiden, The Nether-
lands, and Great Ormond Street Hospital (GOSH), London, 
UK, between January 2003 and July 2015, were included. In 
case of multiple HCTs per patient, all transplantations were 
included. Patients using other serotherapy drugs (antithy-
mocyte globulin; ATG) within the same conditioning regi-
men were excluded, including patients who received alem-
tuzumab following allergic reactions to ATG in the same 
conditioning. Additionally, patients who received any type 
of serotherapy in a 3-month period before this HCT were 
excluded from this analysis. No restrictions were applied 
on the timing and dose of alemtuzumab, or any patient-, 
disease- or transplantation-related factors. Data were col-
lected and samples were taken after informed consent was 
given through the parents and/or the child in accordance 
with the Declaration of Helsinki. Ethical committee approval 
was acquired through trial numbers P01.028 (Leiden) and 
V0904 (London).
Alemtuzumab  (Campath®; Genzyme, Cambridge, MA, 
USA) was administered as an intravenous infusion, usually 
6–8 days before HCT, for 4–5 consecutive days. In Lon-
don, alemtuzumab was the standard choice for serotherapy, 
while in Leiden, alemtuzumab was reserved for patients 
with selected immune deficiencies and myelodysplastic 
syndrome. Patients with hemophagocytic lymphohistiocy-
tosis (HLH) received alemtuzumab 15 days before trans-
plantation. Although the dose of alemtuzumab varied, most 
patients were administered a cumulative dose of 1 mg/kg 
(5 × 0.2 mg/kg/day), with a substantial number of patients 
receiving alemtuzumab at a cumulative dose of 0.5 mg/kg at 
the treating physician’s discretion. Patients received antihis-
tamines and high-dose corticosteroids around alemtuzumab 
infusions, in accordance with institutional guidelines. A 
small number of patients received in vitro lymphodepletion 
of the graft by direct addition of alemtuzumab 20 mg to the 
graft infusion bag 30 min prior to infusion [27]. Due to the 
small time window compared with the long half-life between 
adding alemtuzumab to the infusion bag containing the graft 
and the graft infusion itself, the full amount of alemtuzumab 
was assumed to be administered with infusion of the graft 
in these patients.
Conditioning regimens were administered according to 
(inter)national protocols (European Society for Bone Mar-
row Transplantation, Working Parties’ recommendations). 
GvHD prophylaxis consisted of cyclosporin A (controlled 
with TDM at trough levels of 150–250 μg/L) combined with 
either prednisolone (cord blood transplants) or methotrexate 
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(matched unrelated donor). Patients receiving an identical 
related donor transplantation or CD34 selected graft did 
not receive any additional GvHD prophylaxis. All patients 
received gut decontamination and were treated in positive 
pressure, particle free, air-filtered, isolation rooms.
Samples for PK measurements were taken before and 
after each infusion, followed by one sample weekly in 
patients from Leiden, until approximately + 70 days after 
HCT, while, in London, three samples were available 
per patient—on the day of HCT (day 0), and + 14 and 
+ 28 days after HCT. The samples around infusion were 
taken at ± 15 min before and after infusion, which, given 
the long half-life of alemtuzumab, can be seen as true trough 
and peak levels. Samples were prospectively collected and 
measured in batches.
2.2  Measurement of Alemtuzumab Concentration 
and Anti‑Alemtuzumab Antibodies
2.2.1  Quantitative Flow Cytometry (Q‑FACS) Assay
The laboratory in London, measuring samples from part of 
the London population, used a quantitative flow cytometry 
(Q-FACS) assay. Alemtuzumab levels were measured using 
Q-FACS assays, in modifications of the method described 
[28]. In short, 1 × 106 human T-cell line-78 (HUT-78) T cells 
were incubated using fourfold dilutions of patients’ serum 
in phosphate-buffered saline (PBS), followed by wash-
ing and incubation with conjugated secondary antibodies 
(Alexa Fluor 647 labeled goat anti-human IgG; Life Tech-
nologies). Incubations were carried out at room tempera-
ture for 30 min each. To construct a reference curve, HUT 
cells were incubated with known amounts of alemtuzumab 
(range 10–0.01 µg/mL) containing 25% human serum. Cells 
were washed and mean fluorescence intensity (MFI) was 
measured on an FACS Calibur machine (Becton Dickinson 
Biosciences, Franklin Lakes, NJ, USA). The lower limit of 
quantitation for alemtuzumab in this assay was 0.1 µg/mL, 
with a linear response from 0.01 to 0.1 μg/mL. The assay 
did not change over time.
2.2.2  Enzyme‑Linked Immunosorbent Assay
All samples from Leiden, and part of the samples from 
London, were measured in Leiden using an enzyme-linked 
immunosorbent-based assay (ELISA) [29]. Microtiter plates 
(Corning Corporation, Corning, NY, USA) were coated 
with a human polyclonal anti-idiotype antibody to alemtu-
zumab (Geoff Hale Developments, Marston, Oxford, UK), 
diluted in PBS at a concentration of 0.5 µg/mL, by incubat-
ing overnight at 4 °C, followed by blocking with 2% casein 
in PBS. Samples, controls, and a diluted standard range of 
alemtuzumab (25.000–100 µg/mL, diluted in 10% pooled 
human serum) were applied and incubated at 37 °C for 1 h 
at room temperature. After washing, bound alemtuzumab 
was detected with biotin-labeled anti-idiotype antibody, 1 h 
at room temperature, followed by streptavidin poly-horserad-
ish peroxidase (HRP; Sanquin, 8000145253, 2 µg/mL), for 
30 min. The lower limit of detection was 0.01 µg/mL. The 
assay did not change over time.
In both assays, alemtuzumab spiked sera were used as 
controls. The results of 146 samples tested with both ELISA 
NC anti-idiotype and Q-FACS were compared. For the cor-
relation, only samples with a measured alemtuzumab con-
centration > 0.1 µg/mL in Q-FACS were used. Electronic 
supplementary Fig. S1 shows the reasonable correlation of 
both assays (R2 = 0.89).
2.2.3  Population Pharmacokinetic (PK) Analysis
For analysis of the PK data, non-linear mixed-effects mod-
eling was employed using NONMEM 7.3.0 (Icon Devel-
opment Solutions LLC, Hanover, MD, USA). R version 
3.2.3 and Pirana version 2.8.2 were used for preparation 
and visualization of data. First-order conditional estimation 
(FOCE) with interaction was used throughout the model 
development. Alemtuzumab concentrations were logarith-
mically transformed and simultaneously fitted. Samples that 
were reported to be below the limit of quantification (BLQ), 
which only occurred in the tail-end of the concentration, 
were set at half the BLQ, with subsequent samples being 
removed in accordance with method M6 [30]. Interindivid-
ual variability on PK parameters was assumed to follow a 
log-normal distribution, and were implemented in the model 
according to Eq. 1:
where Pi is the individual or post hoc value of the param-
eter in the ith individual, Ppop is the population mean for this 
parameter, and 휂i is the interindividual variability of the ith 
person, which samples from a normal distribution with a 
mean of 0 and a variance of ω2. An additive error model 
was used, which, due to logarithmically transformed data, 
should be seen as a proportional error model. Here, the jth 
observation for the ith individual was described using Eq. 2:
where Yi,j is the observed concentration, Cpred,i,j is the jth 
predicted concentration for individual i, and 휀 is the error, 
sampled from a normal distribution with a mean of 0 and a 
variance of σ2.
Several criteria were applied in the process of model 
building and selection. A decrease in objective function 
value (OFV) over 3.84 points between nested models was 
considered statistically significant; this correlated with 
p < 0.05 based on a Chi-square distribution with 1 degree 
(1)Pi = Ppop × e휂i ,
(2)Yi,j = Cpred,i,j + 휀,
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of freedom. Goodness-of-fit (GOF) plots were evaluated, 
including observed versus both individual- and popula-
tion-predicted concentrations, as well as conditional 
weighted residuals (CWRES) versus time and observed 
concentrations. Additionally, parameter uncertainty and 
휂shrinkage were evaluated to assess model performance.
Interoccasion variability (IOV) was tested to assess 
changes in parameters between the respective doses 
according to Eq. 3:
where, compared with Eq. 1, κi is the IOV for the mth occa-
sion. Individual PK parameters (post hocs) were estimated 
using the POSTHOC option in NONMEM.
The elimination of antibodies is often dependent on the 
concentration of substrate [31, 32], therefore non-linear 
elimination pathways were explored. No data on target 
concentrations over time (i.e. CD52 or lymphocytes) were 
available, therefore full target-mediated drug disposition 
(TMDD) models, as previously described, were not per-
sued [32, 33]. Instead, non-linear elimination pathways 
were explored by incorporating clearance (CL) described 
by Michaelis–Menten kinetics (Eq. 4):
where V is the elimination rate, Vmax is the maximum elimi-
nation rate, C is the alemtuzumab concentration, and Km is 
the Michaelis–Menten constant, the concentration at which 
50% of the maximum elimination rate is reached.
2.2.4  Covariate Model
Patient characteristics, including body size parameters 
(actual body weight, age, body surface area), and transplant- 
and disease-specific variables (sex, underlying disease, stem 
cell source, number of HCTs received, treatment center) 
were studied as possible covariates for their relation with 
PK parameters. In line with previous reports, the role of lym-
phocyte counts on alemtuzumab PK was also investigated 
as CD52 is almost exclusively expressed on these cells. Cell 
counts drawn before the first infusion of alemtuzumab were 
available; the lymphocyte counts are greatly reduced after 
the first dose and were therefore not taken in the included 
patients. Therefore, we considered baseline lymphocyte 
counts drawn within 48 h before infusion of the first alem-
tuzumab dose as a covariate. No other biochemical markers 
were evaluated as a covariate.
To assess the covariate relations, post hocs, interindivid-
ual variability, and CWRES were plotted against covariates, 
both before and after inclusion of the covariates, to evaluate 
potential relationships. Stepwise covariate modeling was 
performed in parallel. Lastly, only those covariates where 
(3)Pi = Ppop × e휂i+휅m ,
(4)V =
Vmax × C
Km + C
.
a physiological or pharmacological mechanism could be 
hypothesized were included. Continuous covariates such as 
age and body weight were tested in a linear and power func-
tion (Eqs. 5 and 6):
where Pi and  Covi are the parameter and covariate value for 
the ith individual, respectively, Ppop is the population mean 
for this parameter, and  Covmedian is the standardized value 
for the covariate. In the linear relationship equation (Eq. 5), 
l represents the slope factor of the linear function, while, in 
the power relationship equation (Eq. 6), k is the scaling fac-
tor. Additionally, because the influence of bodyweight on CL 
appeared more complex, variations of Eq. 6 were explored, 
where k is dependent on the covariate value of the ith indi-
vidual, as proposed by Wang et al. [34]. and implemented in 
several other models [35, 36]. Evaluated variations included 
a maximum effective concentration (Emax) approach and a 
power function according to Eq. 7:
where k is the exponential scaling factor in Eq. 6, k0 is the 
value for the exponent for an individual with a hypothetical 
bodyweight of 0 kg, kmax is the maximum decrease of the 
exponent, k50 is the bodyweight at which 50% of kmax is 
reached, and ϒ is the Hill coefficient determining the steep-
ness of the sigmoidal decline. In the power function, a rep-
resents the coefficient and b is the exponent. This model 
was developed in order to reflect the changing influence of 
weight with age during growth of the child.
Potential covariates were evaluated using forward inclu-
sion and backward elimination, with a significance level 
of < 0.005 (− 7.9 points in OFV) and < 0.001 (− 10.8 points 
in OFV), respectively. Building of the covariate model was 
comparable with the development of the structural model. 
In addition, after inclusion of a covariate, a decline in unex-
plained interindividual variability had to be achieved before 
inclusion into the final model [37].
2.2.5  Model Evaluation
The model was thoroughly evaluated for robustness. To 
assess the predictive performance of the model, bootstrap 
(5)Pi = Ppop ×
(
1 +
(
Covi
Covmedian
)
× l
)
,
(6)Pi = Ppop ×
(
Covi
Covmedian
)k
,
(7)k = k0 −
kmax × BW
훶
i
k훶
50
+ BW훶
i
,
(7)k = a × BWb,
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analyses were performed, stratified on treatment center. One 
thousand datasets were created using random selection from 
the original dataset; the final model was fit to each data set. 
For each parameter, median values from the thousand fits for 
each parameter, as well as 95% confidence intervals (CIs), 
were compared with parameter estimates of the final model.
In addition, a normalized prediction distribution of errors 
(NPDE) was performed, where the prediction discrepancies 
are simulated, taking into account the correlation between 
observations in the same individual and the predictive dis-
tribution [38]. Finally, prediction-corrected visual predictive 
checks (VPCs) were created to assess the predictive per-
formance of the final model compared with the measured 
concentrations.
3  Results
3.1  Patients
A total of 206 patients receiving 212 HCTs were included 
from the two treatment centers (Table 1). Median age was 
4.8 years (range 0.2–19; 28 infants < 1 year) and median 
body weight was 17.2 kg. Fifty-four percent of patients 
received a cumulative alemtuzumab dose of 0.9–1.1 mg/
kg, while 35% received a cumulative dose of < 0.9 mg/kg. 
The first dose was a median of 8 days before the graft infu-
sion, ranging from 0 days (alemtuzumab added the trans-
plant itself) to 21 days before transplantation. Most patients 
(52%) received an HCT to treat an immune deficiency; the 
most frequently used stem cell source was bone marrow. A 
total number of 1146 concentration samples were available 
for this analysis (median 5.4 samples per patient) (Fig. 1). 
A total of 180 samples (112 from Leiden patients, 68 from 
London patients, 14% of all samples) were BLQ; 76 were set 
as 0.05 μg/mL, 104 samples were excluded. The majority of 
the samples (84%, collected in 136 patients) were measured 
in Leiden. The dataset was pooled in order to include all 
patients treated in the treatment period. No optimal sam-
pling design was incorporated. In patients from Leiden, 
peak-trough and washout samples were available. For the 
patients in London, samples were available on the day of 
stem cell infusion (day 0; 8 days after the first infusion of 
alemtuzumab), day + 14 and day + 28. 
3.2  Structural PK Model
A two-compartment model best described the PK of alem-
tuzumab (Table 2, Fig. 2, and electronic supplementary 
Fig. S7). Compared with a one-compartment model, the 
two-compartment model was superior in terms of GOF 
plots and OFV (253 points decrease in OFV; p < 0.001). 
However, large residual standard errors in the parameters 
associated with distribution were observed, as well as a high 
dependency on initial values. To address this issue, model 
simplification was applied, with peripheral volume of distri-
bution (V2) being estimated as a factor of the central volume 
of distribution (V1), as previously shown in the literature 
[39–41], which made the model more stable and independ-
ent on initial values. This model yielded a decrease of 158 
points in OFV compared with the one-compartment model 
(p < 0.001), and showed comparable GOF plots compared 
with the full two-compartment model. A three-compartment 
model proved unstable, showing inaccurate parameter esti-
mates. A proportional error model was incorporated in the 
model. 
Looking at the individual concentration-time profiles, 
non-linear PK features are suggested by the bell-shaped 
curve at higher concentrations (Fig. 1b). Models with only 
non-linear CL, as well as models with parallel linear and 
non-linear CL, were therefore evaluated. In this study, 
compared with only linear CL, both models resulted in a 
substantial decrease in OFV, with the model with parallel 
CL pathways being clearly superior (− 39 and − 99 points 
in OFV for only non-linear and parallel CL with three and 
four additional parameters, respectively). Therefore, alemtu-
zumab elimination was described using linear and non-linear 
CL, which was parameterized using the Michaelis–Menten 
equation incorporating the maximum elimination rate 
(Vmax) and Michaelis–Menten constant (Km), depicting the 
concentration at which the elimination rate was 50% of the 
Vmax. Besides a decrease of 99 points in OFV, the addi-
tion of non-linear CL to the linear CL model resulted in an 
improvement in GOF plots. The Michaelis–Menten constant 
could be well-estimated and fell within the observed con-
centration range (Fig. 1). The relative contribution of linear 
and non-linear CL is depicted in electronic supplementary 
Fig. S2. No improvement of the model in terms of OFV and 
GOF plots was observed when including IOV on any of the 
parameters.
3.3  Covariate Model
According to the predefined criteria, the covariate analysis 
showed that actual body weight and age were correlated 
with central volume of distribution and linear CL. Actual 
body weight proved the best predictor for these param-
eters, both in terms of decrease in OFV and improvement 
of GOF plots (Fig. 3). The inclusion of body weight as a 
power function (Eq. 6) on V1 yielded a decrease in OFV 
of 92 points. In addition, the effect of body weight on 
linear CL was parameterized as a body-weight-dependent 
exponent (BDE), in which the exponent differs according 
to body weight (Eq. 7, Fig. 3) [35, 36]. Including a BDE 
parameterization on linear CL gave a better description 
of the relation with body weight, especially in smaller 
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Table 1  Patient characteristics
HCTs hematopoietic cell transplantations, TBI total body irradiation, IQR interquartile range
London Leiden Total
Number of patients 139 67 206
Number of HCTs 139 73 212
Male sex (%) 66 67 67
Age, years [median (IQR)] 4.0 (1.6–8) 7.3 (3–14) 4.8 (1.8–10)
Weight, kg [median (IQR)] 16.0 (11–25) 21.0 (14–47) 17.2 (11–32)
Number of samples (mean per patient) 343 (2.5) 803 (11.0) 1146 (5.4)
Location of concentration measurements (% of samples)
 Leiden 47 100 84
 London 52 0 16
Starting day for alemtuzumab [median (IQR)] 8 (8–8) 6 (5–8) 8 (7–8)
Lymphocyte count before conditioning (× 109) 
[median (IQR)]
0.74 (0.62–1.6) 0.54 (0.16–1.0) 0.74 (0.53–1.5)
Cumulative dose, mg/kg (%)
 < 0.9 37 31 35
 0.9–1.1 50 62 54
 > 1.1 13 7 11
Diagnosis (%)
 Hematologic malignancy 17 40 25
 Immune deficiency 62 34 52
 Bone marrow failure 15 25 18
 Metabolic disease 5 0 4
 Benign hematology 1 1 1
Stem cell source (%)
 Bone marrow 61 60 61
 Peripheral blood stem cells 39 32 36
 Cord blood 0 8 3
Conditioning regimen (%)
 Reduced intensity conditioning 43 66 51
 Chemotherapy-based myeloablative 51 29 43
 TBI-based myeloablative 6 5 6
Fig. 1  Concentration-time plots 
of all patients from LUMC 
(open circles) and GOSH (dots) 
on a a normal scale and b a log 
scale. Dashed line represents 
the Michaelis–Menten constant 
Km. The start of the first alem-
tuzumab treatment is defined as 
T = 0. LUMC Leiden University 
Medical Center, GOSH Great 
Ormond Street Hospital
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children, as seen in plots of interindividual variability on 
CL versus body weight, and gave a 52-point decline in 
OFV. The exponent in this model varied from 3.69 in chil-
dren with a body weight of 5 kg to 0.41 in patients weigh-
ing 80 kg (electronic supplementary Fig. S3). Finally, 
body weight was introduced as a covariate on intercom-
partmental distribution based on the described relationship 
in the literature. This yielded another decrease in OFV of 
22 points, and gave a substantial improvement in GOF 
plots split for age (Fig. 2).
Baseline lymphocyte counts were evaluated as a covar-
iate for CL. Data on baseline lymphocyte counts were 
missing in 56 patients; these were set at median baseline 
lymphocyte count in the population. Baseline lymphocyte 
counts did not influence any PK parameters, including lin-
ear and non-linear CL (electronic supplementary Figs. S4 
and S5). Even when removing patients with missing values 
for baseline lymphocytes from the dataset, no effect of 
baseline lymphocytes on CL were found. The full model 
code can be found in the electronic supplementary data.
3.4  Internal Validation
The final model with body weight on volume of distribution, 
intercompartmental distribution, and in a BDE parameteri-
zation on linear CL was stable in bootstrap analysis (96.1% 
successful). The bootstrap was stratified on treatment center 
to account for the density of sampling. Median and 95% CIs 
were in line with the model estimations and residual stand-
ard errors (Table 2). The NPDE analysis showed normally 
distributed errors, with no major trends in NPDE versus time 
or NPDE versus predictions. The prediction-corrected VPC 
shows model simulations to be in line with model predic-
tions, both in high and low concentrations (Fig. 4).
4  Discussion
Alemtuzumab plays an important role in preventing GvHD 
and graft failure following pediatric HCT, as well as the 
occurrence of early T-cell IR [1, 2, 6, 42]. In this large 
cohort of children, we describe the population PK of alem-
tuzumab in an HCT setting. The proposed model adequately 
Table 2  Parameter estimates 
and bootstrap results
Cl linear clearance, WT body weight (kg), WTmedian median population body weight (17.3 kg), V1 central 
volume of distribution, V2 peripheral volume of distribution, Q intercompartmental clearance, Vmax maxi-
mum transport rate for saturable clearance pathway, Km Michaelis–Menten constant saturable distribution 
for saturable clearance pathway, RSE relative standard error
Dataset [esti-
mate (%CV)]
Shrinkage 1000 bootstrap replicates 
(96.1% successful)
Median 5th–95th percentile
Structural model
 Cli = CLpop ×
(
WT
WTmed
)(a×WT)b
  CLpop (L/day) 0.25 (15) 0.24 0.16–0.33
  a 0.038 (21) 0.043 0.021–0.086
  b − 0.79 (22) − 0.6 − 1.48 to − 0.2
 V1,i = V1,pop ×
(
WT
WTmed
)c
  V1,pop (L) 2.13 (9) 2 1.54–2.4
  c 0.58 (13) 0.63 0.47–0.8
  V2,pop (factor of V1) 0.7 (15) 0.74 0.55–1.14
 Qi = Qpop ×
(
WT
WTmed
)d
  Q (L/day) 0.18 (18) 0.2 0.14–0.65
  d 0.74 (21) 0.75 0.12–1.26
  Vmax,pop (AU/day) 0.42 (19) 0.4 0.25–0.81
  Km,pop (AU/L) 1.38 (29) 1.48 0.84–3.5
Random variability
 Interindividual variability on CL (%) 104 (7) 16 104 88–129
 Interindividual variability on V1 (%) 63 (15) 19 57 44–76
 Interindividual variability on Km (%) 138 (8) 34 139 114–168
 Proportional residual error (%) 34 (8) 18 34 29–40
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describes the observed concentrations, and was extensively 
validated. Actual body weight was found to be a predictor for 
CL and central volume of distribution, and should therefore 
be taken into account for dosing of alemtuzumab.
In the developed model, alemtuzumab elimination was 
best described using a parallel linear and saturable CL path-
way. This is in line with antibody pharmacology, where both 
target binding and non-specific degradation are the major 
elimination pathways [43, 44]. The implemented param-
eterization with parallel linear and non-linear CL path-
ways, the latter using Michaelis–Menten kinetics, is often 
used, particularly when the antibody targets a non-soluble 
protein [31]. As lymphocytes harbor the vast majority of 
CD52 [45] the peripheral blood baseline lymphocyte count 
was considered as a covariate for elimination. However, no 
impact of baseline lymphocyte counts on any PK parameters 
was found. A possible explanation could be that an excess 
of drug is introduced in relation to the amount of CD52, 
thereby minimizing the effect of target availability. However, 
this should be kept in mind when significantly decreasing 
the administered dose as cell counts are known to influence 
alemtuzumab CL at lower dosages [13].
A previous study by Mould et al. described the population 
PK of alemtuzumab in adults treated for chronic lymphatic 
leukemia (CLL) [13]. Alemtuzumab PK were described 
using a two-compartment model incorporating saturable 
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Fig. 2  Goodness-of-fit plots of the final model: individual predicted versus observed concentrations of alemtuzumab in all patients, split by quar-
tiles of body weight. a < 11 kg; b 11–17.3 kg; c 17.3–32 kg; and d > 32 kg. Lines represent the line of unity (x = y)
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CL, no linear CL was included in the model. White blood 
cell (WBC) count on Vmax was found to be the only covari-
ate predicting PK, indicating a higher maximal CL rate in 
patients harboring more targets for alemtuzumab. Although 
the population and treatment setting in the current study 
is significantly different, our parameter estimates in terms 
of total CL and central volume of distribution are broadly 
similar to their results. Importantly, the dosage and usage of 
alemtuzumab in a CLL setting is markedly different from 
conditioning in HCT. Where alemtuzumab is used long-term 
for tumor suppression in CLL, its use in HCT is rapid and 
results in full depletion of recipient T cells. This is reflected 
in the substantially higher dose in HCT, which leads to full 
depletion of lymphocytes over the course of 2 days. This 
may explain why the CLL study did indeed find that cell 
counts impacted the elimination of alemtuzumab, while, in 
an HCT setting using high doses of alemtuzumab, the role of 
cell counts on the PK is minor. Another population PK study 
including 17 children, presented as conference proceeding, 
described alemtuzumab PK in pediatric HCT using a one-
compartment model, with only weight as a covariate on CL 
and volume [18]. No relationship between lymphocytes and 
PK parameters was identified in this study.
Few studies have investigated the dose–effect or expo-
sure–effect relationship of alemtuzumab in terms of IR. 
Nonetheless, T-cell reconstitution, especially of CD3+ and 
CD4+ T cells, is suggested to be slower following higher 
exposures of alemtuzumab [1, 8, 46]. In terms of clinical 
outcome parameters, higher doses of alemtuzumab have 
been associated with a lower incidence of GvHD [1, 4, 5, 
10, 12, 47, 48]. In one study investigating alemtuzumab 
concentration rather than dosage, those patients with higher 
concentrations on the day of HCT had less acute GvHD, but 
more mixed chimerism and poor IR; however, no impact on 
survival was demonstrated based on the concentrations on 
the day of HCT [1].
There are some weaknesses in this study. Foremost, the 
study was not designed for population PK analysis, and 
therefore the timing of sample collection was not optimized. 
As a consequence, approximately only one-third of patients 
had peak/trough concentrations available, making the esti-
mation of volumes of distribution difficult. This is reflected 
in a minor underestimation of peak concentrations. Second, 
samples were measured in two laboratories using differ-
ent assays. Although validation studies show an adequate 
correlation between both assays, and laboratory was not a 
Fig. 3  Interindividual variabil-
ity on clearance (upper panels) 
and central volume of distribu-
tion (lower panels), both before 
(left plots) and after (right plots) 
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covariate in the model, the model might have been more 
stable when all samples were measured in the same labora-
tory. Furthermore, the unexplained variability on CL and 
Km remains substantial. This makes it more difficult to give 
dose recommendations for future patients, and TDM may 
be needed to correct for unexplained variability in the PK. 
Next, interindividual variability is rather high and cannot be 
well explained by the introduction of the available covari-
ates. This particularly applies to the high variability on CL 
of 104%. This limits the possibilities of the model to predict 
individual concentrations in future patients, and may suggest 
that TDM is needed.
Finally, the parameterization of the covariate effect 
of body weight on linear CL was optimized to describe 
changes across the entire weight range. However, data 
from only a few individuals (n =10) with a body weight 
higher than 60 kg were available. As a consequence, the 
predictive value above this weight range may be lower 
than for other parts of the curve. This applies particularly 
to the fact that linear CL is expected to slightly decrease 
from a body weight of 60 kg onwards (decrease of 1.2%).
5  Conclusions
We have developed and extensively validated a population 
PK model that adequately describes alemtuzumab PK over 
the entire pediatric age range. This model incorporates par-
allel linear and non-linear elimination pathways, reflecting 
TMDD as frequently observed in antibody kinetics. Actual 
body weight was identified as a covariate on CL, volume 
of distribution, and intercompartmental distribution, the 
former as a BDE. Although CD52 is mainly expressed on 
lymphocytes, no relationship between baseline lymphocyte 
counts and alemtuzumab elimination was found. Evalua-
tion of the current dosing regimen showed that exposure 
varies across age and is therefore suboptimal.
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Fig. 4  Evaluation studies. a–c NPDE. a Histogram of the NPDE, 
with the solid line representing a normal distribution with a mean of 
0 and variance of 1. b NPDE versus time. c NPDE versus predictions. 
Grey blocks represent the 95% CI of the NPDE. Prediction-corrected 
VPC on d a normal axis and e a logarithmically transformed axis. 
Solid lines represent the 5% CIs, median and 95% CI of the data; dot-
ted lines represent the 5% CI, median and 95% CI of the simulations; 
dark grey blocks represent the median of the simulations; and light 
grey blocks represent the 95% CIs of the simulations. NDPE normal-
ized prediction distribution of errors, CI confidence interval, VPC 
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This model can be used for further studies to investigate 
optimal alemtuzumab exposure. Once the therapeutic win-
dow is identified, the model may serve as the basis for an 
individualized dosing regimen for children receiving an 
HCT. Using this regimen, optimal alemtuzumab exposure 
can be achieved, potentially improving clinical outcome 
in these children.
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